Immunosuppressant agonists

Abstract

The invention provides a composition for improving an action of an immunosuppressant, comprising insulin-like growth factor I or its analog as an active ingredient.

1 . A composition for improving an action of an immunosuppressant, comprising insulin-like growth factor I or an analog thereof as an active ingredient.  
     
     
         2 . The composition of  claim 1 , wherein the improving effect is an enhancing effect of the immunosuppressive action of -the immunosuppressant.  
     
     
         3 . The composition of  claim 2 , wherein the action of the immunosuppressant is its prophylactic or therapeutic action on the liver diseases.  
     
     
         4 . The composition of  claim 2 , wherein the action of the immunosuppressant is its anagenetic action on the liver and/or hepatic cell enlargement or growth promoting action.  
     
     
         5 . The composition of  claim 2 , wherein the action of the immunosuppressant is its prophylactic or therapeutic action on the graft rejection following a liver transplantation.  
     
     
         6 . The composition of claims  1 ˜ 5 , wherein the immunosuppressant is an immunosuppressive macrolide compound.  
     
     
         7 . The composition of  claim 6 , wherein the macrolide compound is FK506.  
     
     
         8 . The composition of claims  1 ˜ 5 , wherein the immunosuppressant is cyclosporin A.  
     
     
         9 . The composition of  claim 1 , wherein the action of the immunosuppressant is its side effect and the improvement thereon is alleviation or inhibition of its side effect.  
     
     
         10 . The composition of  claim 9 , wherein the side effect of the immunosuppressant is suppression of choleresis, suppression of bile acid secretion and/or cholestasis.  
     
     
         11 . The composition of  claim 9 , wherein the side effect of the immunosuppressant is the side effect of cyclosporin A.  
     
     
         12 . The composition of  claim 1 , comprising an immunosuppressant and insulin-like growth factor I or its analog.  
     
     
         13 . A method of improving the action of an immunosuppressant, which comprises administering an effective amount of insulin-like growth factor I or an analog thereof.  
     
     
         14 . A use of insulin-like growth factor I or an analog thereof for manufacturing a composition for improving an action of an immunosuppressant.  
     
     
         15 . An insulin-like growth factor I-producing composition comprising an immunosuppressive macrolide compound as an active ingredient.  
     
     
         16 . The insulin-like growth factor I-producing composition claimed in  claim 15 , wherein the macrolide compound is FK506.  
     
     
         17 . A method of inducing the production of insulin-like growth factor I, which comprises administering an effective amount of an immunosuppressive macrolide compound.  
     
     
         18 . A use of an immunosuppressive macrolide compound for manufacturing an insulin-like growth factor I-producing composition.  
     
     
         19 . A choleretic composition, bile acid secretion promoting composition and/or therapeutic composition for cholestasis, which comprises an insulin-like growth factor I-producing compound as an active ingredient.  
     
     
         20 . The composition claimed in  claim 19 , wherein the insulin-like growth factor I-producing compound is a macrolide compound.  
     
     
         21 . The composition claimed in  claim 20 , wherein the macrolide compound is FK506.  
     
     
         22 . A method of promoting choleresis, a method of promoting bile acid secretion and/or a method of treating cholestasis, which comprises administering an effective amount of an insulin-like growth factor I-producing compound.  
     
     
         23 . Use of an insulin-like growth factor I-producing compound for the production of a choleretic composition, bile acid secretion promoting composition and/or therapeutic composition for cholestasis.